Researchers at the University of Toronto have revealed the binding action of the bacterial toxin responsible for toxic shock syndrome. Although similar to the toxin that causes diarrhea, the two proteins behave differently due to a short amino acid sequence, which the researchers were able to manipulate.
Researchers at the Emory Vaccine Center have demonstrated that a novel adjuvant, 3M-052, can aid long-lasting immunity against HIV in rhesus monkeys. This could have implications for developing successful vaccines against HIV, influenza and COVID-19.
Rebiotix (MN, USA) recently announced positive preliminary results from an ongoing clinical trial investigating the use of an investigational microbiota-based formulation, RBX2660, for the reduction of C. diff infection.
Researchers at Scripps Research Institute have used the blood of recovered COVID-19 patients to identify potent antibodies that protect against SARS-CoV-2. The study, published in Science, has shown the antibodies’ successful use in animal models and human cell cultures.
Dexamethasone, a steroid drug typically used to treat inflammation in conditions such as arthritis and asthma, has recently been tested as part of the Recovery trial at Oxford University (UK), and results are looking positive.
A recent analysis of COVID-19 cases suggests that up to 45% of SARS-CoV-2 infections may be asymptomatic. This highlights the need for expansive testing and contact tracing to quash the pandemic.
Scientists have investigated the genetic variation in immunity against seven viruses including the SARS-COV-2. The results reveal some HLA variants that may provide the most effective immune response to the viruses.
Researchers at Rush University Medical Center (IL, USA) demonstrated that astrocytes, a type of brain cell can spread the HIV virus to peripheral organs, even when undergoing combination antiretroviral therapy (cART). Suggesting major improvement to current HIV treatments.
Researchers have repurposed cancer immunotherapy tools to identify regions of SARS-CoV-2 to target with a vaccine. They believe the use of this strategy could help develop a vaccine that provides long-term protection from COVID-19.
Researchers from Princeton University have uncovered an antibiotic molecule capable of killing both Gram-negative and Gram-positive bacteria using two simultaneous mechanisms, while also avoiding antibiotic resistance.